ITGAM and leukemia: HO1‐inhibiting lipid‐polymer hybrid nanoparticle (T‐hNP) actively targeted to human leukemia cells by engineered antibody and passively targeted to CD11b+ myeloid cells in a bone marrow niche of human AML‐bearing orthotopic mouse model.